Logo

PharmaShots Weekly Snapshots (March 20 - 24, 2023)

Share this

PharmaShots Weekly Snapshots (March 20 - 24, 2023)

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency

Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE 

Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer Drug Rigosertib

Date: Mar 24, 2023 | Tags: Onconova Therapeutics, Pangea Biomed, Rigosertib, Nivolumab, Biomarkers, Squamous Cell Carcinoma, ENLIGHT platform, Biotech

Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasis

Date: Mar 24, 2023 | Tags:  Boehringer Ingelheim, Spevigo, spesolimab, Generalized Pustular Psoriasis, Regulatory, Health Canada, Marketing Authorization 

AbbVie Reports P-III Study (INSPIRE) Results of Skyrizi (risankizumab) in P-III Induction Study (INSPIRE) for Ulcerative Colitis

Date: Mar 24, 2023 | Tags: AbbVie, Skyrizi, Risankizumab, Ulcerative Colitis, Clinical Trial, P-III, INSPIRE, Induction Study  

AstraZeneca’s Calquence (acalabrutinib) Receives the NMPA’s Approval for Mantle Cell Lymphoma

Date: Mar 24, 2023 | Tags: AstraZeneca, Calquence, acalabrutinib, Mantle Cell Lymphoma, Regulatory, NMPA, Approval 

Macomics Signs a Worldwide Drug Discovery Collaboration Agreement with Ono to Discover and Develop Macrophage-Targeting Antibody Therapy for Cancer

Date: Mar 24, 2023 | Tags: Macomics, Ono, Macrophage-targeting, Antibody, Cancer, ENIGMACT macrophage drug discovery platform, Pharma

Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea

Date: Mar 23, 2023 | Tags: Ono Pharmaceutical, Opdivo, nivolumab, Yervoy, ipilimumab, Esophageal Squamous Cell Carcinoma, Regulatory, MFDS 

Ancora Heart Reports 12 Month Results of AccuCinch System for the Treatment of Patients with Heart Failure

Date: Mar 23, 2023 | Tags: Ancora Heart, AccuCinch System, Heart Failure, Clinical Trial, MedTech

Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease

Date: Mar 23, 2023 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, Chronic Obstructive Pulmonary Disease, Clinical Trial, P-III, BOREAS Trial 

Incyte’s Zynyz (retifanlimab-Dlwr) Receives the US FDA’s Approval for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

Date: Mar 23, 2023 | Tags: Incyte, Zynyz, retifanlimab-Dlwr, Merkel Cell Carcinoma, Regulatory, US, FDA, Approval 

Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders

Date: Mar 23, 2023 | Tags: Biohaven, BHV-8000, TLL-041, Immune-Mediated Brain Disorders, Pharma

Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression

Date: Mar 23, 2023 | Tags: Dewpoint Therapeutics, Novo Nordisk, AI technology platform, Insulin Resistance, Diabetes Progression, Pharma

TaiGen Entered into an Exclusive License Agreement with Joincare to Develop and Commercialize TG-1000 in China

Date: Mar 22, 2023 | Tags: TaiGen, Joincare, TG-1000, China, Pharma

Medtronic Collaborated with NVIDIA to Advance the Development of AI in the Healthcare Industry

Date: Mar 22, 2023 | Tags: Medtronic, NVIDIA, AI, NVIDIA Holoscan & NVIDIA IGX, GI Genius, colorectal cancer, DigiHealth

Jacobio Entered into a Clinical Collaboration with Merck to Evaluate JAB-BX102 + Keytruda (pembrolizumab) for Solid Tumors

Date: Mar 22, 2023 | Tags: Jacobio, Merck, JAB-BX102, Keytruda, pembrolizumab, pablizumab, Solid Tumors, Pharma

Lumicell Reports the NDA Submission of Lumisight Optical Imaging Agent to the US FDA for the Detection and Removal of Intraoperative Breast Cancer

Date: Mar 22, 2023 | Tags: Lumicell, Lumisight Optical Imaging Agent, Intraoperative Breast Cancer, Regulatory, US, FDA, NDA 

Altimmune Reports 24 Week Interim Analysis Results of Pemvidutide in P-II Trial (MOMENTUM) and P-Ib Trial for Obesity and Type 2 Diabetes

Date: Mar 22, 2023 | Tags: Altimmune, Pemvidutide, Obesity, Type 2 Diabetes, Clinical Trial, P-II, MOMENTUM, P-Ib Trial 

Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

Date: Mar 22, 2023 | Tags: Kite, Yescarta, Large B-cell Lymphoma, Clinical Trial, P-III, ZUMA-7 Study

OrsoBio Reports the First Patient Dosing of TLC-3595 in P-IIa Clinical Trial for the Treatment of Type 2 Diabetes

Date: Mar 21, 2023 | Tags: OrsoBio, TLC-3595, Type 2 Diabetes, Clinical Trial, P-II Trial

Selecta and Sobi Report P-III Trial (DISSOLVE I & II) Results of SEL-212 for Chronic Refractory Gout

Date: Mar 21, 2023 | Tags: Selecta, Sobi, SEL-212, Chronic Refractory Gout, Clinical Trial, P-III, DISSOLVE I & II Trial

Regeneron’s Dupixent (dupilumab) Receives EC’s Approval as First Targeted Medicine for Severe Atopic Dermatitis

Date: Mar 21, 2023 | Tags: Regeneron, Dupixent, dupilumab, Atopic Dermatitis, Regulatory, EC, Approval 

CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

Date: Mar 21, 2023 | Tags: Bristol Myers Squibb, CHARM Therapeutics, Small Molecule, Drug Discovery, DragonFold deep learning platform, Pharma

Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer

Date: Mar 21, 2023 | Tags: Gilead, Nurix, NX-0479, GS-6791 Cancer, Biotech

BioNTech Signs an Exclusive Worldwide License and Collaboration Agreement with OncoC4 to Co-Develop and Commercialize ONC-392

Date: Mar 21, 2023 | Tags: BioNTech, OncoC4, ONC-392, Solid Tumor, Non-small cell lung cancer, Pharma

Coya Therapeutics Signs an Agreement with Dr. Reddy’s Laboratories to License its Proposed Biosimilar Abatacept to Develop and Commercialize COYA 302

Date: Mar 20, 2023 | Tags: Coya Therapeutics, Dr. Reddy’s Laboratories, Abatacept, COYA 302, neurodegenerative diseases, Pharma

UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

Date: Mar 20, 2023 | Tags: UCB, Bimekizumab, Hidradenitis Suppurativa, Clinical Trial, P-III, BE HEARD I, BE HEARD II Trial

Takeda Reports P-IIb Trial Results TAK-279 for the Treatment of Plaque Psoriasis

Date: Mar 20, 2023 | Tags: Takeda, TAK-279, Plaque Psoriasis, Clinical Trial, P-IIb Trial 

DermaSensor Presents Pooled Analysis Results from the (DERM-ASSESS III) & (DERM-SUCCESS) Clinical Studies of Skin Cancer Detection Device

Date: Mar 20, 2023 | Tags: DermaSensor, Device, Skin Cancer, Clinical Trial, DERM-ASSESS III, DERM-SUCCESS Clinical, Clinical Trial, MedTech

Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023

Date: Mar 20, 2023 | Tags: Galderma, Nemolizumab, Prurigo Nodularis, Clinical Trial, P-III, OLYMPIA 2 Trial, AAD, 2023

Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Atopic Hand and Foot Dermatitis at AAD 2023

Date: Mar 20, 2023 | Tags: Regeneron, Dupixent, dupilumab, Atopic Hand, Foot Dermatitis, Clinical Trial, P-III Trial, AAD, 2023

Related Post: PharmaShots Weekly Snapshots (March 13 - 17, 2023)


Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions